Pharmacokinetics of pinokalant, a new nonselective cation channel blocker in the rat

Arzneimittel-Forschung/Drug Research

Volumn 51, Issue 12, 2001, Pages 947-954

  Leusch, A ^a   Eichhorn, B ^a   Busch, U ^a   Ensinger, H A ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

CAS 143482 63 7; Cation channel blocker; LOE 908; Pinokalant, pharmacokinetics, rat; Quinoline; Traumatic brain injury

Indexed keywords

1 ISOQUINOLINEACETAMIDE 3,4 DIHYDRO 6,7 DIMETHOXY ALPHA PHENYL N,N BIS[2 (2,3,4 TRIMETHOXYPHENYL)ETHYL]METHANESULFONATE; 2 (3,4 DIHYDRO 6,7 DIMETHOXY 1 ISOQUINOLINYL) 2 PHENYL N,N BIS[2 (2,3,4 TRIMETHOXYPHENYL)ETHYL]ACETAMIDE; PINOKALANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; BLOOD BRAIN BARRIER; BRAIN INJURY; DRUG BLOOD LEVEL; DRUG EXCRETION; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; RAT;

EID: 0035664311     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300143     Document Type: Article

References (20)

1. New models of focal cerebral ischaemia
2. Neuroprotective effects of a novel broad-spectrum cation channel blocker, LOE 908 MS, on experimental focal ischemia: A multispectral study
3. The novel compound LOE 908 attenuates acute neuromotor dysfunction but not cognitive impairment or cortical tissue loss following traumatic brain injury in rats
4. Novel potent inhibitor of receptor-activated nonselective cation current in HL-60 cells
5. Inhibition of a store-operated Ca2+ entry pathway in human endothelial cells by the isoquinoline derivative LOE 908
6. LOE 908 blocks delayed rectifier type potassium channels in PC12 cells and cortical neurons in culture
7. Analytical methods validation: Bioavailibility, bioequivalence and pharmacokinetic studies
8. Physiological parameters in laboratory animals and humans
9. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics
10. Metabolism of 6,7-dimethoxy4-(p-chlorobenzyl)-isoquinoline. I. Single-dose pharmacokinetics in the rat and mouse
11. Metabolism and penetration through blood-brain barrier or parkinsonism-related compounds. 1,2,3,4-tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline
12. Effect of plasma protein binding on in vivo activity and brain penetration of Glycine/NMDA receptor antagonists
13. Hydrophobicity and central nervous system agents: On the principle of minimal hydrophobicity in drug design
14. Why are non-sedating antihistamines non-sedating?
15. Overcoming of vinblastine resistance by isoquinolinesulfonamide compounds in adramycin-resistant leukemia cells
16. Interrelationships between excretion of drug via urine and bile
17. Bestimmung der bindung von Sulfonamiden an Serumeiweiß mit der ultrazentrifuge